Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA149421 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Transcriptional profiling of human acute myelogenous leukemia (AML) CD34+ cells treated with 5 μM fenretinide. Two timepoints included are 6h, 12h, covering the apoptosis-induction time window of AML CD34+ cells responsing to the fenretinide treatment. We studied gene expression series in human AML CD34+ cells with or without 5 μM fenretinide treatment by cDNA microarray analysis. Several signal transduction pathways are involve, including stress response, NF-kappaB inhibition and p53 inhibition (p<0.05). These findings indicate fenretinide may represent a promising candidate for targeting AML-initiating cells.
2011-11-30 | GSE33243 | GEO
Project description:Transcriptional profiling of human acute myelogenous leukemia (AML) CD34+ cells treated with 5 μM fenretinide. Two timepoints included are 6h, 12h, covering the apoptosis-induction time window of AML CD34+ cells responsing to the fenretinide treatment. We studied gene expression series in human AML CD34+ cells with or without 5 μM fenretinide treatment by cDNA microarray analysis. Several signal transduction pathways are involve, including stress response, NF-kappaB inhibition and p53 inhibition (p<0.05). These findings indicate fenretinide may represent a promising candidate for targeting AML-initiating cells. 6-condition experiment, untreated AML CD34+ cells vs. fenretinide-treated AML CD34+ cells,including 2 time points, for each point the untreated and 5 μM fenretinide treated, independently grown and harvested. Untreated was used to counteracting the background.
2011-11-30 | E-GEOD-33243 | biostudies-arrayexpress
Project description:Dysregulated gene expression networks in human acute myelogenous leukemia stem cells
| PRJNA117785 | ENA
Project description:NF1 inactivation in adult acute myelogenous leukemia
| PRJNA126677 | ENA
Project description:Chronic myelogenous leukemia hematopoietic stem cells
| PRJNA106075 | ENA
Project description:Evolution of human BCR-ABL1 leukemia-initiating cells
| PRJNA227485 | ENA
Project description:Evolution of human BCR-ABL1 leukemia-initiating cells
| PRJNA227486 | ENA
Project description:Fenretinide has shown its antitumor activity in many tumor types with low cytotoxicity to normal cells. Recently, we have shown that fenretinide could eradicate chronic myeloid leukemia stem/progenitor cells and spheres from ovarian cancer. In this study, we investigate whether fenretinide could selectively target sphere cells of colon cancer. Using high-throughtput microarray system, we identified GO terms and pathway signatures enriched in fenretinide treated HT29 cells and HT29 derived sphere cells.
2016-04-03 | GSE66983 | GEO
Project description:Time-series transcriptome profilings of control and Fenretinide-treated human NB4 cells
| PRJNA116137 | ENA
Project description:Treatment of primary acute myelogenous leukemia (AML) specimens with parthenolide (PTL)
| PRJNA99367 | ENA